A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome

Trial Profile

A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome

Suspended
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs NDV 3 (Primary)
  • Indications Candidiasis; Staphylococcal infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Aug 2017 Status changed from recruiting to suspended.
    • 11 May 2017 Planned End Date changed from 29 Dec 2017 to 29 Dec 2018.
    • 11 May 2017 Planned primary completion date changed from 15 Nov 2017 to 29 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top